Inhibition of DNA-PK suppresses tumor growth in preclinical models
Highlights from one of the most active therapeutic clinical trials programs in the U.S.
Established lymphoma/leukemia therapy also targets glioma stem cells
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy